Cytori Therapeutics (CYTX) Misses Q4 EPS by 4c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- U.S. economy adds 29,000 jobs in September
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- BofA's Hartnett sees risk-off mood lasting until dollar peaks
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
March 8, 2018 4:25 PM ESTSAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (Cytori or the Company) today announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate activity and clinical development.Â
Fourth quarter and full year 2017 net loss was $4.3 million, or $0.10 per share, and $22.7 million, or $0.70 per share, respectively. Operating cash burn for the fourth quarter and full year 2017 was approximately $4.2 million and $18.1 million, respectively.... More
